The United Kingdom (UK) has announced that it will be the first country to implement a national program using the same vaccine to protect newborns following vaccinating pregnant women and older adults against Respiratory Syncytial Virus (RSV).
Each year in the UK, RSV infections are responsible for 20 to 30 infant deaths and around 9,000 hospital admissions in those aged over 75.
First National RSV Vaccination Program Launches in the UK
National RSV Vaccination Program Launches in the UK
The United Kingdom (UK) has announced that it will be the first country to implement a national program using the same vaccine to protect newborns following vaccinating pregnant women and older adults against Respiratory Syncytial Virus (RSV).
Each year in the UK, RSV infections are responsible for 20 to 30 infant deaths and around 9,000 hospital admissions in those aged over 75.
Odds of IBS, Functional Dyspepsia Increased After Acute Gastroenteritis Episode
Significantly increased odds seen for irritable bowel syndrome, functional dyspepsia compared with nonexposed controls
Funding for Phase Four Vaccine Studies Needed
While many people have recently learned about the clinical trial research process, most are unaware these studies are conducted according to a plan containing an essential fourth type of study: phase four.
These late-stage studies, often called post-marketing research, are conducted after the U.S. FDA has approved a vaccine or medication.
Clinical research leaders wrote a comprehensive Perspective, suggesting an innovative method for increasing the number of phase four studies.
Funding for Phase Four Vaccine Studies Needed
While many people have recently learned about the clinical trial research process, most are unaware these studies are conducted according to a plan containing an essential fourth type of study: phase four.
These late-stage studies, often called post-marketing research, are conducted after the U.S. FDA has approved a vaccine or medication.
Clinical research leaders wrote a comprehensive Perspective, suggesting an innovative method for increasing the number of phase four studies.
Childhood Immunizations Stalled in 2023
The latest World Health Organization (WHO) and UNICEF estimates of national immunization coverage highlight the need for vaccination catch-up, recovery, and system-strengthening efforts.
The WHO announced today the global childhood immunization coverage stalled in 2023, leaving 2.7 million additional children un- and under-vaccinated compared to 2019.
More than half of unvaccinated children live in 31 countries.
Hospital-Onset SARS-CoV-2 Infection During Omicron Linked to Morbidity
Hospital-onset SARS-CoV-2 remained associated with increased morbidity and mortality during omicron era
England Offers Ample Access to UTI Vaccines
The United Kingdom's NHS recently updated its urinary tract infection (UTI) webpage to explain that some people may experience persistent UTI symptoms, and current urine tests may not detect chronic infections caused by bacteria embedded in the bladder lining.
Chronic UTIs, also known as recurrent UTIs (rUTIs), are typically treated with antibiotics. The NHS advises patients to ask their GP to refer them to a specialist if they experience rUTIs.
Which Vaccines Are Recommend for France's Summer Olympics
As we approach the Paris 2024 Olympic and Paralympic Games in late July and August, a recent study has looked into the possibility of using wastewater surveillance to detect priority pathogens that can be monitored during these events.
On July 11, 2024, the researchers published a list of 60 important pathogens in Eurosurveillance to be monitored for public health during the 2024 Games.
Second-Gen Passive Immunization Significantly Protects Infants from RSV
The New England Journal of Medicine recently published the results of a randomized controlled clinical trial that reaffirms the estimated effectiveness of Beyfortus™ (nirsevimab), a second-generation monoclonal antibody that reduces the risk of hospitalization for respiratory syncytial virus (RSV)- associated bronchiolitis in infants by 83%.
This finding is significant since RSV is the leading cause of bronchiolitis, resulting in about three million hospitalizations each year worldwide.